Literature DB >> 9215867

Anti-tumor mechanisms of 3'-ethynyluridine and 3'-ethynylcytidine as RNA synthesis inhibitors: development and characterization of 3'-ethynyluridine-resistant cells.

S Tabata1, M Tanaka, Y Endo, T Obata, A Matsuda, T Sasaki.   

Abstract

To discover the mechanisms of anti-tumor action of 3'-ethynyluridine (EUrd) and 3'-ethynylcytidine (ECyd), we established an EUrd-resistant variant from human fibrosarcoma HT-1080 cells. The cells were cross-resistant to ECyd. Uridine/cytidine kinase activity diminished in the resistant cells. The incorporation of EUrd and ECyd into the RNA fraction in the resistant cells was less than that of the parental cells. EUrd-triphosphate inhibited RNA synthesis by human RNA polymerase II. The results led us to conclude that EUrd and ECyd are phosphorylated by uridine/cytidine kinase to 5'-triphosphates, and that their triphosphates might inhibit RNA polymerase.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9215867     DOI: 10.1016/s0304-3835(97)00188-2

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  5 in total

1.  A nucleoside anticancer drug, 1-(3-C-ethynyl-β-D-ribo-pentofuranosyl)cytosine (TAS106), sensitizes cells to radiation by suppressing BRCA2 expression.

Authors:  Shunsuke Meike; Tohru Yamamori; Hironobu Yasui; Masato Eitaki; Akira Matsuda; Masami Morimatsu; Masakazu Fukushima; Yasundo Yamasaki; Osamu Inanami
Journal:  Mol Cancer       Date:  2011-07-28       Impact factor: 27.401

2.  Molecular mechanisms of substrate specificities of uridinecytidine kinase.

Authors:  Wataru Tanaka; Mitsuo Shoji; Fumiaki Tomoike; Yuzuru Ujiie; Kyohei Hanaoka; Ryuhei Harada; Megumi Kayanuma; Katsumasa Kamiya; Toyokazu Ishida; Ryoji Masui; Seiki Kuramitsu; Yasuteru Shigeta
Journal:  Biophys Physicobiol       Date:  2016-06-08

3.  Antitumor activity and pharmacokinetics of TAS-106, 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)cytosine.

Authors:  Y Shimamoto; A Fujioka; H Kazuno; Y Murakami; H Ohshimo; T Kato; A Matsuda; T Sasaki; M Fukushima
Journal:  Jpn J Cancer Res       Date:  2001-03

4.  Cellular and biochemical mechanisms of the resistance of human cancer cells to a new anticancer ribo-nucleoside, TAS-106.

Authors:  Yuji Shimamoto; Hiromi Kazuno; Yuko Murakami; Atsushi Azuma; Katsuhisa Koizumi; Akira Matsuda; Takuma Sasaki; Masakazu Fukushima
Journal:  Jpn J Cancer Res       Date:  2002-04

5.  Sensitivity of human cancer cells to the new anticancer ribo-nucleoside TAS-106 is correlated with expression of uridine-cytidine kinase 2.

Authors:  Yuji Shimamoto; Katsuhisa Koizumi; Hiroyuki Okabe; Hiromi Kazuno; Yuko Murakami; Fumio Nakagawa; Akira Matsuda; Takuma Sasaki; Masakazu Fukushima
Journal:  Jpn J Cancer Res       Date:  2002-07
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.